Literature DB >> 18586296

Regulation of maturation and activating potential in CD8+ versus CD8- dendritic cells following in vivo infection with vaccinia virus.

Rama D Yammani1, Sharmila Pejawar-Gaddy, Thaddeus C Gurley, Eric T Weimer, Elizabeth M Hiltbold, Martha A Alexander-Miller.   

Abstract

DC maturation is known to be a necessary step in the generation of an effective immune response. We have used vaccinia virus (VACV) as a model to investigate the regulation of DC subsets in vivo following infection. While a number of in vitro studies have shown that DC infected with VACV fail to undergo maturation, the effect of VACV infection on the maturation of and cytokine production by DC subsets in vivo remains less defined. We have found that following systemic infection with vaccinia virus, both CD8+ and CD8- dendritic cells are infected. The number of infected DC peaked at 6 h and was highly decreased by 24 h post-infection. In both subsets, there was evidence of generalized upregulation of costimulatory molecules. Surprisingly, this included vaccinia infected DC, suggesting the regulation of DC maturation in vivo is much more complex and likely influenced by DC extrinsic signals. However, while we observed generalized upregulation of costimulatory molecules, IL-12 production was restricted to a subset of non-infected cells in both the CD8+ and CD8- DC populations. Importantly, the control of IL-12 production was differentially dependent on MyD88 signaling. IL-12 production was ablated in the absence of MyD88 in CD8- DC, while it was unchanged in CD8+ DC. These findings provide new insights into the control of DC maturation in vivo and demonstrate that the regulation of maturation in vivo following virus infection can be differentially controlled in distinct types of DC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586296      PMCID: PMC2615475          DOI: 10.1016/j.virol.2008.05.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal.

Authors:  O Schulz; A D Edwards; M Schito; J Aliberti; S Manickasingham; A Sher; C Reis e Sousa
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

2.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

Authors:  A Bowie; E Kiss-Toth; J A Symons; G L Smith; S K Dower; L A O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  The role of Toll-like receptors and MyD88 in innate immune responses.

Authors:  S Akira; K Hoshino; T Kaisho
Journal:  J Endotoxin Res       Date:  2000

4.  Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo.

Authors:  Christopher C Norbury; Daniela Malide; James S Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Nat Immunol       Date:  2002-02-04       Impact factor: 25.606

5.  Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes.

Authors:  R Drillien; D Spehner; A Bohbot; D Hanau
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

6.  Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.

Authors:  J Engelmayer; M Larsson; M Subklewe; A Chahroudi; W I Cox; R M Steinman; N Bhardwaj
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

Review 7.  Function and activation of NF-kappa B in the immune system.

Authors:  P A Baeuerle; T Henkel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

8.  Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus.

Authors:  Ying Xiang; Richard C Condit; Sangeetha Vijaysri; Bertram Jacobs; Bryan R G Williams; Robert H Silverman
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8(+) T cells.

Authors:  Sameh Basta; Weisan Chen; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

Review 10.  Viral mechanisms of immune evasion.

Authors:  A Alcami; U H Koszinowski
Journal:  Trends Microbiol       Date:  2000-09       Impact factor: 17.079

View more
  9 in total

1.  Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection.

Authors:  Georges Abboud; Vikas Tahiliani; Pritesh Desai; Kyle Varkoly; John Driver; Tarun E Hutchinson; Shahram Salek-Ardakani
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

Review 2.  Paramyxovirus activation and inhibition of innate immune responses.

Authors:  Griffith D Parks; Martha A Alexander-Miller
Journal:  J Mol Biol       Date:  2013-09-20       Impact factor: 5.469

3.  Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection.

Authors:  Spencer J Hansen; John Rushton; Alexander Dekonenko; Hitendra S Chand; Gwyneth K Olson; Julie A Hutt; David Pickup; C Rick Lyons; Mary F Lipscomb
Journal:  Virology       Date:  2011-02-21       Impact factor: 3.616

4.  Functional divergence among CD103+ dendritic cell subpopulations following pulmonary poxvirus infection.

Authors:  Nicole M Beauchamp; Rhea Y Busick; Martha A Alexander-Miller
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

Review 5.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

6.  The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus.

Authors:  Yuan Zhao; Carl De Trez; Rachel Flynn; Carl F Ware; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

Review 7.  Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Authors:  Zong Sheng Guo; Zuqiang Liu; Stacy Kowalsky; Mathilde Feist; Pawel Kalinski; Binfeng Lu; Walter J Storkus; David L Bartlett
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

8.  Of mice and humans: how good are HLA transgenic mice as a model of human immune responses?

Authors:  Maya F Kotturi; Erika Assarsson; Bjoern Peters; Howard Grey; Carla Oseroff; Valerie Pasquetto; Alessandro Sette
Journal:  Immunome Res       Date:  2009-06-17

9.  Protein kinase C overexpression does not enhance immune-stimulatory surface markers of vaccinia-infected dendritic cells and DC cell lines.

Authors:  Hartwig P Huemer; Markus Geiger; Wilfried Posch; Nina Krumböck; Friedrich Fresser; Doris Wilflingseder; Florian Uberall
Journal:  Immunol Invest       Date:  2013       Impact factor: 3.044

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.